Aptose Biosciences Inc (APTO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
Oct 18, 2022: Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022
Oct 01, 2022: Aptose Reports Results for the Third Quarter 2022
Sep 13, 2022: Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D.
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company that focuses on developing personalized therapies for the treatment of life-threatening cancers including, acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), certain B-cell malignancies, and other hematologic malignancies. The company’s cancer therapeutics pipeline products include HM43239, a myeloid kinome inhibitor (MKI), CG-806, a FLT3/BTK kinase inhibitor; APTO-253, a MYC oncogene inhibitor and APL-581, a dual BET Bromodomain-Kinase Inhibitor. Its small molecule cancer therapeutics pipeline product programs are designed to provide single agent benefit. The company operates in Canada and the US and has collaborations with biopharmaceutical companies and healthcare centers for the development and commercialization of its pipeline product programs. Aptose is headquartered in San Diego, California, the US.Aptose Biosciences Inc Key Recent Developments
Dec 12, 2022: Aptose Biosciences establishes new At-The-Market FacilityOct 18, 2022: Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022
Oct 01, 2022: Aptose Reports Results for the Third Quarter 2022
Sep 13, 2022: Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D.
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company- Aptose Biosciences Inc - Key Facts
- Aptose Biosciences Inc - Key Employees
- Aptose Biosciences Inc - Key Employee Biographies
- Aptose Biosciences Inc - Major Products and Services
- Aptose Biosciences Inc - History
- Aptose Biosciences Inc - Company Statement
- Aptose Biosciences Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Company Overview
- Aptose Biosciences Inc - Business Description
- R&D Overview
- Aptose Biosciences Inc - Corporate Strategy
- Aptose Biosciences Inc - SWOT Analysis
- SWOT Analysis - Overview
- Aptose Biosciences Inc - Strengths
- Aptose Biosciences Inc - Weaknesses
- Aptose Biosciences Inc - Opportunities
- Aptose Biosciences Inc - Threats
- Aptose Biosciences Inc - Key Competitors
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
- Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
- Aptose Biosciences Inc, Recent Deals Summary
- Dec 12, 2022: Aptose Biosciences establishes new At-The-Market Facility
- Oct 18, 2022: Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022
- Oct 01, 2022: Aptose Reports Results for the Third Quarter 2022
- Sep 13, 2022: Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D.
- Aug 02, 2022: Aptose Reports Results for the Second Quarter 2022
- Jun 27, 2022: Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer
- Jun 19, 2022: Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday August 2 2022
- May 31, 2022: Aptose Biosciences Announces Results of Annual Meeting of Shareholders
- May 09, 2022: Aptose Reports Results for the First Quarter 2022
- May 03, 2022: Aptose Biosciences Announces annual and special meeting
- Methodology
- Ratio Definitions
- About the Publisher
- Contact the Publisher
- Disclaimer
- Aptose Biosciences Inc, Key Facts
- Aptose Biosciences Inc, Key Employees
- Aptose Biosciences Inc, Key Employee Biographies
- Aptose Biosciences Inc, Major Products and Services
- Aptose Biosciences Inc, History
- Aptose Biosciences Inc, Subsidiaries
- Aptose Biosciences Inc, Key Competitors
- Aptose Biosciences Inc, Annual Ratios
- Aptose Biosciences Inc, Interim Ratios
- Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
- Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
- Aptose Biosciences Inc, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- Aptose Biosciences Inc, Performance Chart (2017 - 2021)
- Aptose Biosciences Inc, Ratio Charts
- Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
- Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2016 to YTD 2022
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Viracta Therapeutics Inc
- AbbVie Inc
- Celgene Corp
- BeiGene (Beijing) Co Ltd
- Actinium Pharmaceuticals Inc
- Celator Pharmaceuticals Inc
- Jubilant Therapeutics Inc
- LadRx Corp
- Onconova Therapeutics Inc
